Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

Novartis

Status: Completed

Conditions: Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion; Wet Age Related Macular Degeneration; Diabetic Macular Edema; Retinal Vein Occlusion

Treatments: Other: Ranibizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT01318941

CRFB002A2406

Details and patient eligibility

About

This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in the local product label.

Enrollment: 30,490 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, within age limits as defined by local regulations and local product label, who have previously been treated with, who are currently being treated with or initiating treatment with ranibizumab for any approved indication included in the local product label
• Willing and able to provide informed written consent personally or by legal proxy

Exclusion criteria

• Simultaneous participation in a study that includes administration of any investigational drug or procedure
• Systemic or ocular treatment with any VEGF inhibitor other than ranibizumab in the 90 days prior to enrollment
• Other protocol-defined inclusion/exclusion criteria may apply

Trial design

30,490 participants in 1 patient group

Ranibizumab

Treatment:

Other: Ranibizumab

Other: Ranibizumab